Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. DSGN has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
DSGN stock price ended at $3.54 on Monday, after rising0.85%
The Design Therapeutics Inc stock price increased by 0.85% on the last trading day (19 May 2025), rising from 3.37 to 3.54. Throughout the last trading session, the stock experienced a fluctuation of 6.61% , ranging from a day low of $3.33 to a day high of 3.55. The price has declined in 5 of the last 10 days, resulting in a total change of -18.81% during this period. On the last day, trading volume increase by -15.50K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 54.86K shares were traded, amounting to approximately 189.12K.
DSGN Technical Signals
DSGN(Design Therapeutics Inc Corp) has 3 buy signals and 3 sell signals now. The current trend is downtrend starting from 2025-05-12. The total price change during this trend is -3.04%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of DSGN over the last 5 trading days is 260.35K. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
DSGN Moving Average Analysis
Design Therapeutics Inc's overall moving average trend leans more bearish as of Tuesday, May 20, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $4.76503, and $5.370500000000001. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $2.8059700000000003, and $2.2005. A break-down below any of these levels will issue sell signals.
DSGN Short Selling Analysis
The short sale ratio of Design Therapeutics Inc(DSGN) as of 12 May 2025 is 15.69%, rising from last trading day. With increasing price from 3.50 to 3.62. The short sell activity indicate that short sellers may be anticipating a price reversion.
Technical Signal
Technical Signals Summary
Sell
3
Buy
3
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
3 Bullish Signals
3 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
11.641
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
11.007
Bullish
Moving Average
Price crosses above 5-day SMA
--
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.183
Bearish
Momentum (10 days)
MOM_10 < 0
-1.14
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.142
Bearish
DSGN Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Design Therapeutics Inc(DSGN), our algorithm predicts DSGN's 1-month price at $4.20, with an 19.55%upwardshift. Using a similarity score up to 96.31%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Design Therapeutics Inc (DSGN.O) stock, as of Sunday, May 18, 2025 , forecasts a 19.55% change over the next month, based on its high correlation with RFIL.O stock patterns. The similarity between their price movements over the analyzed periods is 96.31%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
DSGN
No Data
RFIL
Up: 19.55%Similarity: 96.31%
Name
Similarity
Up/Down
RFIL.O
96.31%
+19.55%
FENC.O
95.08%
+10.02%
TWST.O
94.78%
+2.82%
HIMS.N
94.71%
-10.56%
LEU.A
94.62%
+37.74%
TARA.O
94.57%
-9.41%
LUCD.O
94.48%
+5.00%
ANTE.O
94.47%
-32.71%
CLVT.N
94.43%
-6.25%
TBCH.O
94.31%
-5.66%
DSGN Seasonality Analysis
Based on DSGN's historical stock price data across all years, the probability of a positive return in May is40.00%, suggesting it maynotbe an ideal month to invest in DSGN. In contrast,Februaryoffers the highest probability of positive returns at75.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Design Therapeutics Inc (DSGN.O) stock in February has the highest probability of a positive return (75.00%), while January has the lowest probability (0.00%).
Performance Seasonality
The chart shows Design Therapeutics Inc. (DSGN)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Design Therapeutics Inc (DSGN.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. DSGN has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Design Therapeutics Inc (DSGN.O) stock in a year?
The radar chart shows that buying Design Therapeutics Inc (DSGN.O) stock in February has the highest probability of a positive return (75.00%), while January has the lowest probability (0.00%).
How has Design Therapeutics Inc. (DSGN)'s stock price performed over the past three years?
DSGN's stock price fell by -72.88% in 2023,increased by 142.91% in 2024, and went down by 42.63% in 2025.
Is DSGN a buy based on overall technical signals summary?
DSGN has 3 buy signals and 3 sell signals now. Overall the technical rating for DSGN is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of DSGN.
What is the trend of Design Therapeutics Inc (DSGN)'s moving average?
Design Therapeutics Inc's overall moving average trend leans more bearish as of May 20 2025, with 3 negative signals and 1 positive signal.
What is price prediction for DSGN stock next month?
The price prediction chart for Design Therapeutics Inc (DSGN.O) stock, as of May 18 2025, forecasts a 19.55% change over the next month, based on its high correlation with RFIL stock patterns. The similarity between their price movements over the analyzed periods is 96.31%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for DSGN Stock?
DSGN stock is expected to reach **$4.20-$5.00** by the end of 2025, driven by positive Phase 1 data for DT-168 and potential oversold conditions.
What is price prediction 2030 for DSGN Stock?
Design Therapeutics Inc. (DSGN) stock is predicted to reach **$15 by 2030**, driven by potential success in its gene-targeted therapies pipeline, particularly for Friedreich ataxia and Fuchs endothelial corneal dystrophy. The company's focus on innovative treatments and its early-stage clinical trials position it for significant growth if its products gain FDA approval and market adoption. However, the stock carries high risk due to the uncertainty of clinical trial outcomes and regulatory challenges.